Fabrice André
Impact in
- Cancer Research top 0.01%
- Breast Cancer Treatment Studies
- Cancer Genomics and Diagnostics
- Oncology top 0.02%
- HER2/EGFR in Cancer Research
- Cancer Immunotherapy and Biomarkers
Papers in
- Oncology 305
- HER2/EGFR in Cancer Research 106
- Cancer Treatment and Pharmacology 95
- Cancer Immunotherapy and Biomarkers 46
-
- Advanced Breast Cancer Therapies 176
- Lung Cancer Treatments and Mutations 59
- Co-authors
- Jean‐Charles Soria (70 shared papers)Laurence Zitvogel (32 shared papers)Massimo Cristofanilli (34 shared papers)Lajos Pusztai (44 shared papers)Nicholas C. Turner (46 shared papers)Sibylle Loibl (56 shared papers)Suzette Delaloge (92 shared papers)Sherene Loi (63 shared papers)
- Journals
- Journal of Clinical Oncology (132 papers)Annals of Oncology (113 papers)Cancer Research (90 papers)Clinical Cancer Research (22 papers)ESMO Open (17 papers)
- Partner nations
- FranceUnited StatesItaly
In The Last Decade
Fabrice André
645 papers receiving 37.8k citations
Fabrice André's Hit Papers
Peers
Comparison fields: 5 of 180
- Cancer Research 11.3k
- Oncology 15.7k
- Pulmonary and Respiratory Medicine 10.7k
- Immunology 4.2k
- Molecular Biology 12.3k
Countries citing papers authored by Fabrice André
This map shows the geographic impact of Fabrice André's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Fabrice André with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Fabrice André more than expected).
Fields of papers citing papers by Fabrice André
This network shows the impact of papers produced by Fabrice André. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Fabrice André. The network helps show where Fabrice André may publish in the future.
Co-authors
The 25 scholars most cited alongside Fabrice André, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 674 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | Response to Neoadjuvant Therapy and Long-Term Survival in Patients With Triple-Negative Breast Cancer Hit paper breakdown → | 2008 | 2214 |
| 2 | Alpelisib for PIK3CA -Mutated, Hormone Receptor–Positive Advanced Breast Cancer Hit paper breakdown → | 2019 | 1644 |
| 3 | DNA Repair by ERCC1 in Non–Small-Cell Lung Cancer and Cisplatin-Based Adjuvant Chemotherapy Hit paper breakdown → | 2006 | 1323 |
| 4 | Palbociclib in Hormone-Receptor–Positive Advanced Breast Cancer Hit paper breakdown → | 2015 | 1140 |
| 5 | Overall Survival with Palbociclib and Fulvestrant in Advanced Breast Cancer Hit paper breakdown → | 2018 | 813 |
| 6 | Malignant effusions and immunogenic tumour-derived exosomes Hit paper breakdown → | 2002 | 797 |
| 7 | ESMO recommendations on microsatellite instability testing for immunotherapy in cancer, and its relationship with PD-1/PD-L1 expression and tumour mutational burden: a systematic review-based approach Hit paper breakdown → | 2019 | 705 |
| 8 | Use of Biomarkers to Guide Decisions on Adjuvant Systemic Therapy for Women With Early-Stage Invasive Breast Cancer: American Society of Clinical Oncology Clinical Practice Guideline Hit paper breakdown → | 2016 | 581 |
| 9 | Dendritic cell–derived exosomes for cancer therapy Hit paper breakdown → | 2016 | 519 |
| 10 | HER2-Low Breast Cancer: Pathological and Clinical Landscape Hit paper breakdown → | 2020 | 518 |
| 11 | Plasma ESR1 Mutations and the Treatment of Estrogen Receptor–Positive Advanced Breast Cancer Hit paper breakdown → | 2016 | 515 |
| 12 | 2008 | 467 | |
| 13 | 2007 | 461 | |
| 14 | 2004 | 422 | |
| 15 | The Genetic Landscape and Clonal Evolution of Breast Cancer Resistance to Palbociclib plus Fulvestrant in the PALOMA-3 Trial Hit paper breakdown → | 2018 | 415 |
| 16 | 2015 | 403 | |
| 17 | Alpelisib plus fulvestrant for PIK3CA-mutated, hormone receptor-positive, human epidermal growth factor receptor-2–negative advanced breast cancer: final overall survival results from SOLAR-1 Hit paper breakdown → | 2020 | 391 |
| 18 | 2009 | 379 | |
| 19 | 2000 | 359 | |
| 20 | Pembrolizumab versus investigator-choice chemotherapy for metastatic triple-negative breast cancer (KEYNOTE-119): a randomised, open-label, phase 3 trial Hit paper breakdown → | 2021 | 351 |
About Fabrice André
Fabrice André is a scholar working on Oncology, Pulmonary and Respiratory Medicine, Cancer Research, Molecular Biology and Genetics, having authored 674 papers that have together received 38.4k indexed citations. Recurring topics across this work include Advanced Breast Cancer Therapies (176 papers), Cancer Genomics and Diagnostics (109 papers), HER2/EGFR in Cancer Research (106 papers), Breast Cancer Treatment Studies (106 papers), Cancer Treatment and Pharmacology (95 papers), Lung Cancer Treatments and Mutations (59 papers), Cancer Immunotherapy and Biomarkers (46 papers) and PI3K/AKT/mTOR signaling in cancer (43 papers). The work is most often cited by research in Cancer Research (11.3k citations), Oncology (15.7k citations), Pulmonary and Respiratory Medicine (10.7k citations), Immunology (4.2k citations) and Molecular Biology (12.3k citations). Fabrice André has collaborated with scholars based in France, United States and Italy. Frequent co-authors include Jean‐Charles Soria, Laurence Zitvogel, Massimo Cristofanilli, Lajos Pusztai, Nicholas C. Turner, Sibylle Loibl, Suzette Delaloge, Sherene Loi, Gabriel N. Hortobágyi and W. Fraser Symmans. Their work appears in journals such as Journal of Clinical Oncology, Annals of Oncology, Cancer Research, Clinical Cancer Research and ESMO Open.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.